Candida rapid test could reduce mortality rates, study says

04/26/2013 | Medscape (free registration)

The T2Candida rapid blood test created by T2 Biosystems may significantly reduce mortality rates for patients diagnosed with Candida infection, which is the fourth-highest cause of hospital-acquired infections, researchers reported in Science Translational Medicine. Study investigator Dr. Eleftherios Mylonakis of Brown University said time to diagnosis is an important factor in Candida-related mortality and each hour of delay increases the risk.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX